Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02970981 · ClinicalTrials.gov registry record · Phase 2
Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT02970981 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 18 participants.
The verdict
NCT02970981, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-11-29 |
| Est. Completion | 2022-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02970981
The ClinicalTrials.gov registry entry for NCT02970981 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02970981 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02970981 about?
NCT02970981 is a clinical study titled "Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma". The purpose of this study is to assess the safety and tolerability of treatment with Nivolumab in combination with Ipilimumab in subjects with resected Stages IIIB/IIIC/ IV melanoma.
What is the current status of trial NCT02970981?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-11-29. Estimated completion is 2022-05-02.
What interventions are being tested in trial NCT02970981?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02970981?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.